ANTARES PHARMA INC (ATRS) Stock Fundamental Analysis

NASDAQ:ATRS • US0366421065

5.59
0 (0%)
At close: May 23, 2022
5.59
0 (0%)
After Hours: 5/23/2022, 8:12:09 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall ATRS gets a fundamental rating of 3 out of 10. We evaluated ATRS against 193 industry peers in the Pharmaceuticals industry. While ATRS seems to be doing ok healthwise, there are quite some concerns on its profitability. ATRS shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ATRS had positive earnings in the past year.
ATRS Yearly Net Income VS EBIT VS OCF VS FCFATRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M

1.2 Ratios

Industry RankSector Rank
ROA 17.97%
ROE 26.33%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATRS Yearly ROA, ROE, ROICATRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 20 -20 40 -40

1.3 Margins

Industry RankSector Rank
OM 14.87%
PM (TTM) 25.15%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATRS Yearly Profit, Operating, Gross MarginsATRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ATRS has been increased compared to 1 year ago.
  • Compared to 1 year ago, ATRS has an improved debt to assets ratio.
ATRS Yearly Shares OutstandingATRS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 50M 100M 150M
ATRS Yearly Total Debt VS Total AssetsATRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M 250M

2.2 Solvency

  • ATRS has an Altman-Z score of 8.15. This indicates that ATRS is financially healthy and has little risk of bankruptcy at the moment.
  • ATRS has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z 8.15
ROIC/WACCN/A
WACCN/A
ATRS Yearly LT Debt VS Equity VS FCFATRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M 100M 150M

2.3 Liquidity

  • ATRS has a Current Ratio of 2.96. This indicates that ATRS is financially healthy and has no problem in meeting its short term obligations.
  • ATRS has a Quick Ratio of 2.76. This indicates that ATRS is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.76
ATRS Yearly Current Assets VS Current LiabilitesATRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 350.00% over the past year.
  • ATRS shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.99%.
  • Measured over the past years, ATRS shows a very strong growth in Revenue. The Revenue has been growing by 28.65% on average per year.
EPS 1Y (TTM)350%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%533.33%
Revenue 1Y (TTM)22.99%
Revenue growth 3Y42.49%
Revenue growth 5Y28.65%
Sales Q2Q%10.42%

3.2 Future

  • Based on estimates for the next years, ATRS will show a very strong growth in Earnings Per Share. The EPS will grow by 41.76% on average per year.
  • The Revenue is expected to grow by 17.75% on average over the next years. This is quite good.
EPS Next Y-69.78%
EPS Next 2Y-9.18%
EPS Next 3Y8.49%
EPS Next 5Y41.76%
Revenue Next Year15.42%
Revenue Next 2Y18.38%
Revenue Next 3Y17.73%
Revenue Next 5Y17.75%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ATRS Yearly Revenue VS EstimatesATRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M
ATRS Yearly EPS VS EstimatesATRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 20.70, which indicates a rather expensive current valuation of ATRS.
  • The average S&P500 Price/Earnings ratio is at 26.99. ATRS is valued slightly cheaper when compared to this.
  • Based on the Price/Forward Earnings ratio of 68.50, the valuation of ATRS can be described as expensive.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, ATRS is valued quite expensively.
Industry RankSector Rank
PE 20.7
Fwd PE 68.5
ATRS Price Earnings VS Forward Price EarningsATRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 29.05
ATRS Per share dataATRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.18%
EPS Next 3Y8.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ATRS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ANTARES PHARMA INC

NASDAQ:ATRS (5/23/2022, 8:12:09 PM)

After market: 5.59 0 (0%)

5.59

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-10
Earnings (Next)08-03
Inst Owners0.26%
Inst Owner Change0%
Ins Owners6.83%
Ins Owner Change0%
Market Cap955.06M
Revenue(TTM)183.98M
Net Income(TTM)46.28M
Analysts73.33
Price Target6.07 (8.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 20.7
Fwd PE 68.5
P/S 5.19
P/FCF N/A
P/OCF N/A
P/B 5.43
P/tB N/A
EV/EBITDA 29.05
EPS(TTM)0.27
EY4.83%
EPS(NY)0.08
Fwd EY1.46%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.08
BVpS1.03
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 17.97%
ROE 26.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 14.87%
PM (TTM) 25.15%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.76
Altman-Z 8.15
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)350%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%533.33%
EPS Next Y-69.78%
EPS Next 2Y-9.18%
EPS Next 3Y8.49%
EPS Next 5Y41.76%
Revenue 1Y (TTM)22.99%
Revenue growth 3Y42.49%
Revenue growth 5Y28.65%
Sales Q2Q%10.42%
Revenue Next Year15.42%
Revenue Next 2Y18.38%
Revenue Next 3Y17.73%
Revenue Next 5Y17.75%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

ANTARES PHARMA INC / ATRS FAQ

Can you provide the ChartMill fundamental rating for ANTARES PHARMA INC?

ChartMill assigns a fundamental rating of 6 / 10 to ATRS.


What is the valuation status for ATRS stock?

ChartMill assigns a valuation rating of 3 / 10 to ANTARES PHARMA INC (ATRS). This can be considered as Overvalued.


How profitable is ANTARES PHARMA INC (ATRS) stock?

ANTARES PHARMA INC (ATRS) has a profitability rating of 6 / 10.


What is the financial health of ANTARES PHARMA INC (ATRS) stock?

The financial health rating of ANTARES PHARMA INC (ATRS) is 6 / 10.